entertainment -WSS

entertainment

author：hotspot 2025-10-02 21:36:32 - browse：5284

A phone screen displays the webpage of Medicare.gov — coverage from STAT — Adobe

Over the past few weeks, Medicare Advantage insurers demanded that the Biden administration give them higher payment rates for next year. The government’s data on how much people were using health care didn’t match their own data, insurers and lobbyists griped — and therefore they wouldn’t be paid enough to cover those costs.

But the federal government was not persuaded by the industry’s data or lobbying push. The Biden administration and its Medicare agency decided to stick with their proposals from January on Monday, dealing a blow to an insurance industry that has come to rely on Medicare Advantage for a steady stream of profits.

The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% to the baseline payment rates that insurers receive from the government for enrolling older adults and people with disabilities. The stock prices of the largest Medicare Advantage insurers — UnitedHealth, Humana, CVS Health, and Elevance Health — all fell by at least 4% in after-hours trading.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： The problems with dementia villages

focus

leisure time

WSS

Carbon Health diabetes program, a test of data

A letter from the executive editor: STAT UnitedHealth investigation

NIH chief: government has fallen behind pharma on clinical trials

Roivant's CEO is a star, but biotech's black hole persists

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Healthy food access boosts outcomes in two studies

hotspot

entertainment

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Trump demands the U.S. pay no more for drugs than other countries … again

Study on Amgen’s bispecific immunotherapy produces positive data

Apple is now the first public company to be valued at $3 trillion

Ventyx halts psoriasis drug development after lackluster trial results

In Memoriam: Notable people who died in 2023

Results on Novartis prostate cancer therapy could expand its use

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout LOUD podcast: Live from the 2023 STAT Summit

leisure time

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Readout Newsletter: Zepbound, Valneva's vaccine, and more

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

UnitedHealth sued over use of algorithm in Medicare Advantage plans

What is STAT's opinion section for?

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

focus

leisure time

focus

Wikipedia